Platelets in pulmonary hypertension: A causative role or a simple association?

Iranian Journal of Pediatrics

Volumn 22, Issue 2, 2012, Pages 145-157

  Zanjani, Keyhan Sayadpour ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Platelet; Pulmonary hypertension; Pulmonary vascular resistance; Vasoconstriction

Indexed keywords

ANGIOSTATIN; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ESCITALOPRAM; ILOPROST; IMATINIB; NITRIC OXIDE; PHOSPHODIESTERASE III INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PRX 08066; SEROTONIN; SEROTONIN ANTAGONIST; SILDENAFIL; SORAFENIB; TADALAFIL; THROMBOCYTE ACTIVATING FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VARDENAFIL; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; BLOOD VESSEL FUNCTION; CARDIOPULMONARY BYPASS; CELL INTERACTION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONNECTIVE TISSUE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG USE; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART SURGERY; HEMOGLOBINOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; VASCULAR LESION; VASOCONSTRICTION;

EID: 84867522157     PISSN: 10184406     EISSN: 20082150     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Berger G, Azzam ZS, Hoffman R, Yigla M. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr Med Assoc J 2009;11(6):376-9.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54.
3. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease;a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18(4 Part 1):533-47.
4. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J2003;22(2):358-63.
5. Kereveur A, Callebert J, Humbert M, et al. (2000) High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol;20(10):2233-9.
6. Maeda NY, Carvalho JH, Otake AH, et al. Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb Res 2010;125(1):38-43.
7. Stuard ID, Heusinkveld RS, Moss AJ. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med 1972;287(17): 869-70.
8. Suzuki H, Nakasato M, Sato S, et al. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J Exp Med 1997;181(3):379-84.
9. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22(3):451-8.
10. Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999;57:25-48.
11. Eisenberg PR, Lucore C, Kaufman L, et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990;82(3):841-7.
12. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110(3):710-7.
13. Diebold I, Kraicun D, Bonello S, Gorlach A. The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 2008;100(6):984-91.
14. Adatia I, Barrow SE, Stratton PD, et al. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88(5 Pt 1):2117-22.
15. Adatia I, Barrow SE, Stratton PD, et al. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J 1994;72(5):452-6.
16. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-5.
17. Fleming WH, Sarafian LB, Leuschen MP, et al. Serum concentrations of prostacyclin and thromboxane in children before, during, and after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986;92(1):73-8.
18. Greeley WJ, Bushman GA, Kong DL, et al. Effects of cardiopulmonary bypass on eicosanoid metabolism during pediatric cardiovascular surgery. J Thorac Cardiovasc Surg 1988;95(5):842-9.
19. Beghetti M, Barst R, Naeije R, Rubin L. Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Munich: Elsevier GmbH;2006.
20. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther 2008;31(3): 187-99.
21. Sullivan CC, Du L, Chu D, et al. Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. Proc Natl Acad Sci USA 2003;100(21):12331-6.
22. O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007;28(1):169-85.
23. Ni W, Watts SW. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006; 33(7):575-83.
24. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4(1):13-25.
25. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004;94(9):1263-70.
26. Eddahibi S, Morrell N, D'Ortho MP, et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002; 20(6):1559-72.
27. Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med 2004;170(3):252-9.
28. Cerrito F, Lazzaro MP, Gaudio E, et al. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993;53(3):209-15.
29. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99(3):249-54.
30. Lederer DJ, Horn EM, Rosenzweig EB, et al. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 2008;21(1):112-4.
31. Breuer J, Georgaraki A, Sieverding L, et al. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 1996;17(4):214-9.
32. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998;114(5):1276-82.
33. Collados MT, Sandoval J, Lopez S, et al. Characterization of von Willebrand factor in primary pulmonary hypertension. Heart Vessels 1999;14(5):246-52.
34. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34(2):255-65.
35. Kawut SM, Horn EM, Berekashvili KK, et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005;128(4):2355-62.
36. Khoo JP, Zhao L, Alp NJ, et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005;111(16):2126-33.
37. Katusic ZS, D'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 2009;30(1):48-54.
38. Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000;39(1):41-82.
39. Caplan MS, Hsueh W, Sun XM, et al. Circulating plasma platelet activating factor in persistent pulmonary hypertension of the newborn. Am Rev Respir Dis 1990;142(6 Pt 1):1258-62.
40. Chen D, Chen W. Changes of distribution of platelet activating factor in the lung of rats with hypoxic pulmonary hypertension. Chin Med J (Engl) 1996; 109(10):776-9.
41. Ono S, Westcott JY, Voelkel NF. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol 1992;73(3):1084-92.
42. Bixby CE, Ibe BO, Abdallah MF, et al. Role of plateletactivating factor in pulmonary vascular remodeling associated with chronic high altitude hypoxia in ovine fetal lambs. Am J Physiol Lung Cell Mol Physio 2007;293(6):L1475-82.
43. Jurasz P, Alonso D, Castro-Blanco S, et al. Generation and role of angiostatin in human platelets. Blood 2003;102(9):3217-23.
44. Jurasz P, Ng D, Granton JT, et al. Elevated platelet angiostatin and circulating endothelial microfragments in idiopathic pulmonary arterial hypertension: A preliminary study. Thromb Res 2010;125(1):53-60.
45. Jurasz P, Santos-Martinez MJ, Radomska A, Radomski MW. Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. J Thromb Haemost 2006;4(5):1095-106.
46. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92(12):4730-41.
47. Pascaud MA, Griscelli F, Raoul W, et al. Lung overexpression of angiostatin aggravates pulmonary hypertension in chronically hypoxic mice. Am J Respir Cell Mol Biol 2003;29(4):449-57.
48. Italiano JE, Jr., Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111(3):1227-33.
49. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5(3): 487-91.
50. Helotera H, Alitalo K. The VEGF family, the inside story. Cell 2007;130(4):591-2.
51. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130(4):691-703.
52. Damas JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004;110(8):999-1005.
53. Heldin CH. Structural and functional studies on plateletderived growth factor. EMBO J 1992;11(12):4251-9.
54. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22(10):1276-312.
55. Stroobant P, Waterfield MD. Purification and properties of porcine platelet-derived growth factor. EMBO J 1984;3(12):2963-7.
56. DiCorleto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1983;80(7):1919-23.
57. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11(3):554-9.
58. Liu Y, Li M, Warburton RR, et al. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 2007;21(11):2725-34.
59. Otterdal K, Andreassen AK, Yndestad A, et al. Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation. Am J Respir Crit Care Med 2008;177(2):202-7.
60. Rhee JS, Black M, Schubert U, et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004;92(2):394-402.
61. Kopp HG, Hooper AT, Broekman MJ, et al. cells determine angiogenic switch and extent of revascularization. J Clin Invest 2006;116(12):3277-91.
62. Tuder RM, Voelkel NF. Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal 2002;4(5):833-43.
63. Rabinovitch M. Pathophysiology of Pulmonary Hypertension. In: Allen H, DJ. D, RE. S, TF. F (eds). Moss and Adams' Heart Disease in Infants, Children, and Adolescents. Philadelphia: Lippincott Williams & Wilkins; 2008.
64. Coral-Alvarado P, Quintana G, Garces MF, et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 2009;29(9):1017-24.
65. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66(7):940-4.
66. Wigley FM, Lima JA, Mayes M, et al. () The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52(7):2125-32.
67. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29(2):335-49, vii.
68. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009;36(3): 576-82.
69. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford);2008;47 (suppl 5):v2-4.
70. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354(25):2667-76.
71. Okamoto H. Stimulatory autoantibodies to the PDGF receptor in scleroderma. N Engl J Med 2006;355(12):1278;author reply 9.
72. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2011;31(2): 183-9.
73. Asherson RA, Cervera R. Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol 2007;32(2):153-8.
74. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006;5(5):344-8.
75. Coplan NL, Shimony RY, Ioachim HL, et al. Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med 1990;89(1):96-9.
76. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145(5):1196-200.
77. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155(3):990-5.
78. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994;89(6):2722-7.
79. Polos PG, Wolfe D, Harley RA, et al. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest 1992;101(2):474-8.
80. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84(9):618-25.
81. Raghavachari N, Xu X, Harris A, et al. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 2007;115(12):1551-62.
82. Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110(6):2166-72.
83. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell diseaseassociated pulmonary hypertension. Haematologica 2008;93(1):20-6.
84. van Beers EJ, Spronk HM, Ten Cate H, et al. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica 2008;93(5):e42-4.
85. Gramaglia I, Sobolewski P, Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med 2006;12(12): 1417-22.
86. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hypertension due to global impairment in nitric oxide bioavailability. Blood 2007;109(7):3088-98.
87. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 2008;44(8):1506-28.
88. Niu X, Nouraie M, Campbell A, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 2009;4(11):e7956.
89. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97(11):3411-6.
90. Du ZD, Roguin N, Milgram E, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134(3):532-7.
91. Jootar P, Fucharoen S. Cardiac involvement in betathalassemia/hemoglobin E disease: clinical and hemodynamic findings. Southeast Asian J Trop Med Public Health 1990;21(2):269-73.
92. Singer ST, Kuypers FA, Styles L, et al. association with platelet activation and hypercoagulable state. Am J Hematol 2006;81(9):670-5.
93. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, et al. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993;44(1):63-5.
94. Manodori AB, Barabino GA, Lubin BH, Kuypers FA. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood 2000;95(4):1293-300.
95. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293(13):1653-62.
96. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99(1):36-43.
97. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006;92(10):1467-72.
98. Auger WR, Fedullo PF (2009) Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med;30(4):471-83.
99. Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. Curr Opin Cardiol 2008;23(6):555-9.
100. Lang IM, Marsh JJ, Olman MA, et al. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994;90(2): 706-12.
101. Morris TA, Marsh JJ, Chiles PG, et al. Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension. Thromb Res 2007;119(2):257-9.
102. Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006;173(11):1270-5.
103. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 2007;93(9): v1152-8.
104. Riedel B. The pathophysiology and manage-ment of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Int Anesthesiol Clin 1999;37(2):55-79.
105. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension--from bench to bedside? Curr Opin Pharmacol 2009;9(3):281-6.
106. Martin F, Artigas F. Simultaneous effects of pchloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxy-tryptamine in brain and blood. J Neurochem 1992;59(3):1138-44.
107. Zolkowska D, Baumann MH, Rothman RB. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 2008;324(2):791-7.
108. Belohlavkova S, Simak J, Kokesova A, et al. Fenfluramine-induced pulmonary vasocons-triction: role of serotonin receptors and potassium channels. J Appl Physiol 2001;91(2):755-61.
109. Altintas A, Karahan Z, Pasa S, et al. Essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 2007;48(10):1981-7.
110. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987;135(2):294-9.
111. Lopes AA, Maeda NY, Aiello VD, et al. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993;104(5):1455-60.
112. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006;28(5):999-1004.
113. Langleben D, Moroz LA, McGregor M, Lisbona R. Decreased half-life of fibrinogen in primary pulmonary hypertension. Thromb Res 1985;40(4):577-80.
114. Kanai Y, Hori S, Tanaka T, et al. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993;27(9):1619-23.
115. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985;60(1):16-25.
116. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980;77(5):614-25.
117. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25(24):2243-78.
118. Bryniarski L, Pelc-Nowicka A, Zabojszcz M, Mirek Bryniarska E. Dual antiplatelet therapy and antithrombotic treatment: Recommen-dations and controversies. Cardiol J 2009;16(2):179-89.
119. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
120. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000;102(22):2720-5.
121. Saleh JA. Role of iloprost and bosentan in pulmonary arterial hypertension. Niger J Med 2008;17(1):13-9.
122. Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009;135(1):130-6.
123. Tamburrelli C, Crescente M, Izzi B, et al. Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thromb Res 2011;128(5):446-51.
124. Beghetti M, Reber G, de MP, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19(3):518-24.
125. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3(9):2007-18.
126. Toque HA, Teixeira CE, Priviero FB, et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008;154(4):787-96.
127. Murad F. Role of cyclic GMP in the mechanism of action of nitrovasodilators, endothelium-dependent agents and atrial natriuretic peptide. Biochem Soc Trans 1988;16(4):490-2.
128. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003;64(3):533-46.
129. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93(4):280-91.
130. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58(3):488-520.
131. Giordano D, De Stefano ME, Citro G, et al. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001;1539(1-2):16-27.
132. Hanson KA, Burns F, Rybalkin SD, et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998;158(1):279-88.
133. Thusu KG, Morin FC, 3rd, Russell JA, Steinhorn RH. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995;152(5 Pt 1):1605-10.
134. Tsai BM, Wang M, Pitcher JM, et al. Endotheliumdependent pulmonary artery vasorelaxation is dysfunctional in males but not females after acute lung injury. Surgery 2005;138(1):78-84.
135. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998;158 (5 Pt 1):1388-95.
136. Ghofrani HA, Grimminger F. Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors. Dtsch Med Wochenschr 2006;131(49 Suppl 9):S311-4.
137. Ghofrani HA, Olschewski H, Seeger W, Grimminger F. Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie 2002;56(11):665-72.
138. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360(9337):895-900.
139. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104(11): 1218-22.
140. Gudmundsdottir IJ, McRobbie SJ, Robinson SD, et al. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys Res Commun 2005;337(1):382-5.
141. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83(5A):3C-12C.
142. Beghetti M, Sparling C, Cox PN, et al. Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers. Am J Physiol Heart Circ Physiol 2003;285(2):H637-42.
143. Touyz RM, Lariviere R, Schiffrin EL. Endothelin influences pHi of human platelets through protein kinase C mediated pathways. Thromb Res 1995;78(1): 55-65.
144. Jagroop IA, Daskalopoulou SS, Mikhailidis DP. Endothelin-1 and human platelets. Curr Vasc Pharmacol 2005;3(4):393-9.
145. Yousufzai SY, Abdel-latif AA. Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells: activation of phospholipase A2. Exp Eye Res 1997;65(1):73-81.
146. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008;67(8):1121-6.
147. Bassler D, Kreutzer K, McNamara P, et al. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2010;11:CD007802.
148. Tanaka H, Tajimi K, Moritsune O, et al. Effects of milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit Care Med 1991;19(1):68-74.
149. Haraldsson SA, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001;93(6):1439-45.
150. McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006;21(2):217-22.
151. Wesley MC, McGowan FX, Castro RA, et al. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg 2009;108(5):1425-9.
152. Kikura M, Lee MK, Safon RA, et al. The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg 1995;81(1):44-8.
153. Tanaka H, Tajimi K, Miyajima Y, et al. Effects of milrinone on platelet aggregation in swine with pulmonary hypertension. J Crit Care 2000;15(3):113-8.
154. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115(10):2811-21.
155. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32.
156. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353(13):1412-3.
157. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145(2):152-3.
158. Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61(8):736.
159. Ghofrani HA, Barst RJ, Benza RL, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S108-17.
160. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118(20):2081-9.